ArticleTranslational vision science & technology2025
Perifoveal Choriocapillaris Flow Deficits Associated With Cerebrospinal Fluid Aβ42/tau in Presymptomatic Alzheimer's Disease.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Distinct ocular microvascular alterations in Alzheimer's disease and cerebral small vessel disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Inner retinal layer thickness reflects plasma biomarkers in preclinical Alzheimer's disease.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigated the association between swept-source OCTA (SS-OCTA) choriocapillaris flow deficit percentage (CC FD%) and cerebrospinal fluid (CSF) biomarkers in presymptomatic Alzheimer's disease (AD). Methods: Twenty-three cognitively healthy (CH) participants, including those with pathological (CH-PAT) and normal (CH-NAT) Aβ42/tau ratios, underwent lumbar puncture for CSF Aβ42/tau and ptau-181 quantification using electrochemiluminescence assays. OCTA en face images of the choriocapillaris were analyzed for flow deficits within a 6 × 6 mm macular grid and 3- and 6-mm Early Treatment of Diabetic Retinopathy Study (ETDRS) perifoveal rings. The association between CC FD% and CSF Aβ42/tau and CSF ptau-181 levels was evaluated. Results: Perifoveal microvascular changes in the choriocapillaris outer ring (6-mm ETDRS ring) were significantly correlated with the CSF Aβ42/tau ratio in CH-PATs compared to CH-NATs. However, linear regression analysis across all CH participants (CH-PAT + CH-NAT) revealed that only age was significantly associated with CSF ptau-181 levels. Conclusions: Our findings suggest that this cohort is in an early preclinical AD stage, without ptau-181 biomarker evidence of established AD. SS-OCTA measures may complement CSF A/T (amyloid/tau) levels, helping to define transitional stages from CH-NAT to CH-PAT during presymptomatic AD. Translational Relevance: By identifying the transition from normal aging to presymptomatic AD, SS-OCTA metrics combined with biofluid markers could enhance AD oculomics by stratifying disease risk and prioritizing treatment interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.